Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California Stem Cell and BioFocus DPI partner in ALS research
BioFocus DPI will use the high purity, clinical grade human motor neurons to perform assay development and screening for amyotrophic lateral sclerosis (ALS or ‘Lou Gehrig’s disease’) drug
BioFocus DPI will use the high purity, clinical grade human motor neurons to perform assay development and screening for amyotrophic lateral sclerosis (ALS or ‘Lou Gehrig’s disease’) drug
Daiichi Sankyo will purchase 100% of the stock and make a one-time payment of E150 million for the company. Closure of the transaction is subject to clearance under
Steve Guillen, president of MedX Health, said: “We have said publicly that it is our intention to accelerate the development of this new product, aimed at the large
The study, which took place at two sites, consisted of 38 pediatric patients ages 2-12. The mean age was six years. Patients were randomized into two groups: one
Under the agreement, BD (Becton, Dickinson and Company) will fund a research program at Accelr8 through September 30, 2009. The research program includes mutually agreed milestones to support
Quidel will now have access to a new molecular product, particularly suited for the acute care laboratory market. The ProFlu+ test provides a complementary product offering to the
The Southwest Oncology Group (SWOG), a cancer network sponsored by the National Cancer Institute (NCI), is evaluating IMC-A12, ImClone’s fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal
Ferralet 90 contains 90mg of carbonyl iron as well as essential vitamins and minerals to help patients replenish iron stores in an effective, safe and tolerable manner. Ferralet
Under the collaboration, BioSeek will apply its BioMAP Systems to evaluate Merck Serono’s small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead
This application includes a Phase II protocol for Lovaxin C, Advaxis’s lead drug candidate, for the treatment of cervical intraepithelial neoplasia (CIN) to be conducted in the US.